-
Puts Purchased on Cadence Pharmaceuticals (CADX)
Thursday, April 7, 2011 - 12:58pm | 138Shares of Cadence Pharmaceuticals (NASDAQ: CADX) are lower on the session by 1.94%, currently trading at $9.09. The stock has been moving largely higher over the past six weeks and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today...
-
Current Top Percentage Gainers And Losers (XNPT, DGW, IMGN, TPCG, DBLE, GSK, QXM, QTWW, RT, SUPG, NLST)
Thursday, April 7, 2011 - 12:29pm | 291Best 1) XenoPort (NASDAQ: XNPT): An FDA approval for one of its drugs, along with partner GlaxoSmithKline (NYSE: GSK), has shares vaulting. Posting a huge gain of 63.32% to $10.41. 2) Duoyuan Global Water (NYSE: DGW): Stock has exploded 25% to $4.04 since starting the day in negative territory. The...
-
Morning Top Percentage Gainers And Losers (XNPT, GSK, XOMA, BKE, TPCG, BBBY, QXM, RT, NLST, MDRX, BID)
Thursday, April 7, 2011 - 10:28am | 243Best 1) XenoPort (NASDAQ: XNPT): Posting a huge gain of 63.32% to $10.41. An FDA approval for one of its drugs, along with partner GlaxoSmithKline (NYSE: GSK), has shares vaulting. 2) XOMA (NASDAQ: XOMA): Trading up 15.1% to $3.43. 3) TPC Group (NASDAQ: TPCG): Sustaining an 11.6% gain to $36.38...
-
Benzinga's Volume Movers (XNPT, BBBY, BLUD, IMGN)
Thursday, April 7, 2011 - 10:19am | 174XenoPort Inc (NASDAQ: XNPT) shares moved up 67.16% to $10.66 at 10:12 am. The volume of XNPT shares traded was 4112% higher than normal. GlaxoSmithKline Plc (NYSE: GSK) and XNPT received approval from the US Food and Drug Administration (FDA) for the drug Horizant. Bed Bath & Beyond Inc (...
-
Buying Opportunity On Ayala Land, Inc. (ALI)
Thursday, April 7, 2011 - 9:58am | 656“Float like a butterfly, sting like a bee.” Just Like what happened in the Thrilla In Manila, Ayala Land, Inc. or ‘the ALI' of the Philippine Stock Exchange appears to have found its second wind after faltering for about seven months now. You see, ALI had been trading on a...
-
Morning Market Movers (XNPT, AXN, OLCB, MOV)
Thursday, April 7, 2011 - 9:49am | 148XenoPort Inc (NASDAQ: XNPT) climbed 64.89% to $10.52 at 9:45 am. GlaxoSmithKline Plc (NYSE: GSK) and XNPT received approval from the US Food and Drug Administration (FDA) for the drug Horizant. Aoxing Pharmaceutical Company Inc (AMEX: AXN) shares surged 20.00% to $2.70. AXN shares have dropped 11....
-
Pre-Market Top Percentage Gainers and Losers (XNPT, GSK, ZAGG, LOGI, BBBY, PRXL, BLUD, INHX, PWER, INTC, TZOO, KERX)
Thursday, April 7, 2011 - 9:11am | 313Best 1) XenoPort (NASDAQ: XNPT): Posting a huge pre-market gain of 68.61% to $10.77. An FDA approval for its drug, along with partner GlaxoSmithKline (NYSE: GSK), has shares skyrocketing. 2) ZAGG (NASDAQ: ZAGG): Trading up 13% to $9.28. Investors are responding well to an agreement with Logitech...
-
Sanofi-aventis Subsidiary Genzyme Presents New Data from Alemtuzumab Phase 2 MS Trial at 63rd Annual Meeting of the American Academy Of Neurology
Thursday, April 7, 2011 - 9:07am | 87Genzyme, a subsidiary of sanofi-aventis Group (NYSE: SNY), announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011....
-
LifeTech Capital Comments On Merck Acquisition (MRK, ISPH)
Thursday, April 7, 2011 - 8:42am | 131On April 5, 2010, Merck (NYSE: MRK) announced that they are acquiring Inspire Pharmaceuticals (NASDAQ: ISPH) for approximately $430 million, LifeTech Capital reports. “Merck stated goal is to strengthen their ophthalmic portfolio with Inspire's AZASITE (azithromycin ophthalmic solution) for the...
-
Piper Jaffray Comments On XenoPort Following FDA Approval
Thursday, April 7, 2011 - 8:28am | 169Last night, Xenoport (NASDAQ: XNPT) and partner GlaxoSmithKline (NYSE: GSK) announced that the FDA approved of Horizant (gabapentin) for the treatment of restless leg syndrome (RLS). This marks an extraordinary turnabout for the product after the market essentially wrote it off subsequent to the...
-
XenoPort Trading Significantly Higher Pre-Market (XNPT)
Thursday, April 7, 2011 - 8:26am | 42XenoPort (NASDAQ: XNPT) is trading significantly higher pre-market after receiving approval for Horizant, XNPT's drug for restless leg syndrome. At the time of posting, shares of XNPT were trading at $11.01, up 72.57% from Wednesday's close.
-
RBC Capital Upgrades Elan Corporation To Outperform, $10 PT
Thursday, April 7, 2011 - 8:25am | 26RBC Capital Markets has upgraded Elan Corporation (NYSE: ELN) from Sector Perform to Outperform with a $10 price target.
-
Benzinga's Top Upgrades (CRM, SSS, ELN, ICE)
Thursday, April 7, 2011 - 8:22am | 140Salesforce.com Inc (NYSE: CRM) was upgraded by FBR Capital from "market perform" to "outperform." CRM's shares closed at $131.43 yesterday. Salesforce.com's trailing-twelve-month revenue is $1.66 billion. KeyBanc upgraded Sovran Self Storage Inc (NYSE: SSS) from “hold” to “buy.” SSS' shares closed...
-
Benzinga's Top Pre-Market NASDAQ Gainers (XNPT, ZAGG, BBBY, BLUD)
Thursday, April 7, 2011 - 8:16am | 135XenoPort Inc (NASDAQ: XNPT) added 70.85% to $10.90 in the pre-market session. GlaxoSmithKline Plc (NYSE: GSK) and XNPT received approval from the US Food and Drug Administration (FDA) for Horizant. ZAGG Incorporated (NASDAQ: ZAGG) moved up 11.66% to $9.10 in the pre-market session. ZAGG signed an...
-
Deutsche Bank Raises Price Target On Medicis Pharm.
Thursday, April 7, 2011 - 8:11am | 38Deutsche Bank maintains its Buy rating on Medicis Pharmaceutical (NYSE: MRX) and has increased the price target from $36 to $40, “reflecting recent multiple expansions in the sector”. MRX closed yesterday at $34.27.